EADV 2025: Emerging Biologic Therapies in Bullous Pemphigoid

In this MEDtalk from the EADV 2025 Congress, Rikke Bech, MD, PhD, Clinical Associate Professor at the Department of Dermatology and Venereology, Aarhus University Hospital, presents current and emerging treatment options for bullous pemphigoid. She discusses the shift from traditional steroid-sparing agents to novel biologics like Dupilumab and Omalizumab, which show promising efficacy and safety profiles, especially for elderly and comorbid patients.